Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-SPECT CVT
NL-OMON45785Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dabigatran and warfarin in cerebral sinovenous thrombosis (CSVT), sponsored by Boehringer Ingelheim. Started Feb 2017; status: active, not recruiting.
02
Drugs
dabigatranwarfarin
03
Conditions
cerebral sinovenous thrombosis (CSVT)
Beyond the preview
Go deeper on NL-OMON45785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45785.